The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's ...

Clesrovimab joins the monoclonal antibody nirsevimab (Beyfortus), as well as the maternal bivalent RSV prefusion F protein ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

On Friday, Kentucky announced two pertussis deaths in infants over the past 6 months, and neither the infants nor their ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...

Grunting baby syndrome - the medical term is Infant Dyschezia - occurs when your infant is having a poo. They may strain and ...

Estimates varied from 2008 through 2018, with RSV-associated antibiotic prescribing exceeding 10% in peak RSV years and ...

The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Further, the study showed that nirsevimab’s effect was less pronounced in older children (between six and 23 months), ...

Non-communicable diseases such as cancer, cardiovascular disease and diabetes are responsible for 75 percent of deaths ...